News

Merck Serono bags MS licence option
Enlarge image

BusinessGermany

Merck Serono bags MS licence option

06.02.2013 - Merck Serono has secured an exclusive licence option for Opexa Therapeutics’ autologous T cell-based Multiple Sclerosis therapy imilecleucel-T.

Opexa’s Tcelna (imilecleucel-T) therapy currently is tested in a Phase IIb study on patients with Secondary Progressive MS (SPMS), which is less common than relapsing forms of MS that are targeted by Merck’s blockbuster Rebif® (interferon beta-1a)  In case of market entry and successful commercialisation, the US firm could gain US$225m in total from the option and license agreement.

Under the terms of the contract, Opexa will receive an upfront payment of $5 million for granting an option to Merck Serono for the exclusive license of the Tcelna (imilecleucel-T) programme as a treatment of MS. The option may be exercised prior to, or upon completion of, Opexa’s proof-of-concept trial. If Merck Serono opts for the programme, Opexa is eligible for $25m or $15m upfront depending on fulfilment of certain undisclosed conditions. The Germans, in return, would receive worldwide development and commercial rights in MS, excluding Japan. When exercising the option, Merck Serono would have to pay all clinical development, as well as the cost for regulatory authorisation and marketing of the MS programme. Milestone payments to Opexa could sum up to $195m plus a tiered royalty rate from the high single digits to the mid-teens based on net sales.

Under the agreement, Opexa will have an option right to co-fund development, under which the company would participate in economic support for future clinical development of the programme in exchange for additional royalty consideration. In addition to retaining all rights outside of MS as well as retaining the ability to commercialise imilecleucel-T in Japan, Opexa also retains certain manufacturing rights related to the programme. 

Tcelna (imilecleucel-T) is an autologous T cell therapy. After collection of peripheral blood mononuclear cells, myelin-reactive T-cells (MRTCs) raised against selected peptides from myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP) are expanded, irradiated and given back to the patient subcutaneously to trigger a therapeutic immune response.

© eurobiotechnews.eu/tg 

http://www.european-biotechnology-news.com/news/news/2013-01/merck-serono-bags-ms-licence-option.html

2014EU

19.12.2014 We took a look back at 2014: which European Biotechnology News stories topped the charts this year?

R&DEUBelgium

18.12.2014 IMI has launched a €115m call for proposals involving a project in collaboration with the Bill and Melinda Gates Foundation to improve vaccines against whopping cough in children.

PoliticsEUPolandItalySpainUK

16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.

M&ALuxembourg

11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.

StudySwitzerlandEU

10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.

FinancingUKSpain

09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.

CooperationAustria

05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.

FinancingDenmark

03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.

Events

All Events

Current issue

All issues

Product of the week

Products